Caribou Biosciences vs Fate Therapeutics
CRBU and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and FATE compare
Fate Therapeutics is the larger company, worth 3.3 times as much as Caribou Biosciences ($122M against $36.5M).
Caribou Biosciences grew revenue faster over the last twelve months (10.0% versus −23.4% for Fate Therapeutics).
Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1030% compared with −1941% at Fate Therapeutics.
Caribou Biosciences scores higher on the StockData Score (9 against 8 for Fate Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | FATE |
|---|---|---|
| Size and price | ||
| Market cap | $36.5M | $122M |
| Share price | $0.341 | $1.02 |
| Change, 1 year | −82.9% | 5.8% |
| Change, 5 years | −98.1% | −98.1% |
| Beta (5Y) | 1.41 | 3.98 |
| Employees | 97 | 161 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 3 | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× (better) | 18.8× |
| P/B | 0.4× (better) | 0.8× |
| FCF yield | −262% | −86.4% (better) |
| Fair value | $1.29 | $1.34 |
| Margin of safety | 73.7% (better) | 23.8% |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | −23.4% |
| Revenue growth, 5Y average | −2.0% (better) | −26.7% |
| Profitability | ||
| Operating margin | −1091% (better) | −2058% |
| Net margin | −1030% (better) | −1941% |
| FCF margin | −954% (better) | −1627% |
| Return on equity | −78.3% | −60.7% (better) |
| Return on invested capital | – | −553% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.49 (better) | 4.85 |
| Altman Z-score | −7.47 (better) | −8.99 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −66.3% | – |
| Shareholder yield | −66.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 59.9% |
| Held by insiders | 5.7% | 25.7% |
| Insider net buying, 12 months | −$47.5K (better) | −$336K |
| Short interest, % of float | 14.7% | 11.2% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- FATE stock overview
- FATE income statement
- FATE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.